B. Firestone

发表

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.

F. Lombardo, P. Atadja, S. Whitebread, 2011, Journal of medicinal chemistry.

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

Sarah L. Williams, W. Sellers, F. Lombardo, 2016, Journal of medicinal chemistry.

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.

Sarah L. Williams, Robert Koenig, Mitsunori Kato, 2019, Journal of medicinal chemistry.

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

F. Lombardo, L. Hamann, T. Abrams, 2018, Journal of medicinal chemistry.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.

Michael D. Jones, B. Firestone, R. Pagliarini, 2017, ACS medicinal chemistry letters.

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.

Sarah L. Williams, W. Sellers, Z. Deng, 2020, Journal of medicinal chemistry.

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Ping Zhu, Gang Liu, Peter Fekkes, 2016, Nature.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.

B. Firestone, Abran Q. Costales, C. Shafer, 2018, ACS medicinal chemistry letters.

6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.

Sarah L. Williams, Robert Koenig, Mitsunori Kato, 2019, Journal of medicinal chemistry.

IAP inhibitors enhance co-stimulation to promote tumor immunity

N. Hacohen, D. Neuberg, G. Dranoff, 2010, The Journal of experimental medicine.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Characterization of activating mutations of NOTCH3 in T cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies

P. Lemotte, J. Aster, T. Hu, 2016, Oncogene.

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.

B. Firestone, Abran Q. Costales, C. Shafer, 2017, ACS medicinal chemistry letters.

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo.

P. Finan, M. Glick, P. Furet, 2016, ACS medicinal chemistry letters.

The challenge of selecting the 'right' in vivo oncology pharmacology model.

B. Firestone, 2010, Current opinion in pharmacology.

Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.

D. Chin, B. Lagu, B. Firestone, 2013, Journal of medicinal chemistry.

Abstract B27: Correlation between TNFα and LCL161 anti‐tumor activity in patient derived xenograft models of human cancer

Michael P. Morrissey, J. Monahan, D. Porter, 2009 .

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

Sarah L. Williams, W. Sellers, F. Lombardo, 2016, Journal of medicinal chemistry.

The challenge of selecting the 'right' in vivo oncology pharmacology model.

B. Firestone, 2010, Current opinion in pharmacology.